New CLL treatments, the standard of care and the importance of clonal evolution
Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al.
What is the best treatment in the next few years to achieve more treatment-free remission in CML?
The TAP CLARITY study: latest results and future plans